https://www.businesswire.com/news/home/20251103359615/en/Courage-Therapeutics-Completes-Seed-Financing-to-Advance-Its-Melanocortin-Obesity-and-Diseases-of-Wasting-Drug-Programs
Courage Therapeutics, a company developing novel treatments for genetic and dietary obesity and diseases of wasting, today announced it has closed funding le...
couragetherapeuticscompletesseedfinancing
https://www.rcsb.org/structure/7PIV
Active Melanocortin-4 receptor (MC4R)- Gs protein complex bound to agonist NDP-alpha-MSH at 2.86 A resolution.
gs proteinrcsbpdbactivemelanocortin
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2014.00131/full
Inactivating mutations of the melanocortin-4 receptor (MC4R) cause early-onset severe obesity in humans. Comprehensive functional studies show that most of t...
is afrontiersipsennovelpotent